Press Release Thursday 2 February, 2017
Brussels—European public health advocates have called upon the European Commission to make substantial changes to how it funds research and development (R&D) projects for new medicines, to allow for greater public access to the innovations that it helps to fund.
‘’Horizon 2020 continues to allow the privatization of knowledge generated with public funds. To prevent this give away of our knowledge commons the intellectual property rights that are created from these scientific results should be available for sharing and usage under the governance of the European Commission. European citizens should not pay twice for products paid for with European funds. Public incentives for innovation must result in creating public knowledge goods.’’ David Hammerstein, Commons Network.
“Europeans have a right to question why they are funding R&D projects without the European Commission taking simple steps to guarantee that citizens can benefit from discoveries that they helped to fund,” said Tessel Mellema from Health Action International, speaking on behalf of the eight civil society organisations who drafted a joint submission to the Commission.
The call comes following the Commission’s public consultation for the mid-term review of the European Union’s (EU) Research and Innovation programme, Horizon 2020 (H2020), which administers a funding pool of nearly €80 billion.
“At a time when there is real concern within Member States over astronomical prices for new drugs treating cancer and hepatitis C, the European Commission has the opportunity to take real and practical steps to make new biomedical discoveries affordable and accessible across the European Union,” said Aliénor Devalière, one of the report’s authors from Médecins Sans Frontières – Access Campaign.
The joint submission to the Horizon 2020 consultation established six key recommendations that the European Commission should consider during their review process:
- Invest more public funding in biomedical R&D
- Improve public health needs-driven priority setting for biomedical R&D
- Improve and mandate open access publishing and open data
- Ensure public return on public investment and safeguard equitable access to publicly funded health technologies
- Explore alternative incentive mechanisms for more efficient, high-quality R&D
- Increase transparency of research consortium agreements
The submission authors also highlight that the EU has an obligation to ensure a high standard of human health protection across the Union, however major inequalities still exist in the quality of healthcare available in EU Member States.
The full submission to the European Commission consultation can be viewed here online.
The submission to the mid-term review of Horizon 2020 was co-authored by the following organisations:
Health Action International
Medicines Sans Frontieres – Access Campaign
Global Health Advocates
Commons Network
Universities Allied for Essential Medicines
Salud por Derecho
Knowledge Ecology International – Europe
BukoPharmaKampagne
2017-02-02 17:06:45 – Commonsnetwork